Azithromycin versus erythromycin for community-acquired pneumonia: a cost-minimization analysis

Area of Science:

• Pharmacoeconomics
• Infectious Diseases
• Critical Care Medicine

Background:

• Community-acquired pneumonia (CAP) is a common infection requiring antimicrobial treatment.
• Intravenous (i.v.) erythromycin and azithromycin are used in combination therapy for CAP.
• Evaluating the cost-effectiveness of different antibiotic regimens is crucial for healthcare resource allocation.

Purpose of the Study:

• To compare the costs associated with i.v. erythromycin versus i.v. azithromycin.
• To analyze medication use and adverse effect management costs.
• To assess the economic impact of combination antimicrobial therapy for CAP.

Main Methods:

• Retrospective review of medical records from a level 1 trauma center.
• Inclusion of patients receiving i.v. azithromycin or erythromycin as part of CAP combination therapy.
• Data collection on drug acquisition, preparation, administration, and complication management costs.

Main Results:

• Fifty patients were enrolled (25 in azithromycin group, 25 in erythromycin group).
• Average total cost was $66.46 for azithromycin and $96.56 for erythromycin.
• No statistically significant difference in total costs between the two antibiotic groups was observed.

Conclusions:

• Combination antimicrobial therapy for CAP using i.v. azithromycin or erythromycin demonstrates no significant cost difference.
• Further pharmacoeconomic analyses are warranted to guide optimal antibiotic selection in CAP treatment.